Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Proteome Res ; 17(1): 108-118, 2018 01 05.
Artículo en Inglés | MEDLINE | ID: mdl-29043805

RESUMEN

The pathogenic protozoan T. brucei alternates into distinct developmental stages in the mammalian and insect hosts. The mitogen-activated protein kinase (MAPK) signaling pathways transduce extracellular stimuli into a range of cellular responses, which ultimately lead to the adaptation to the external environment. Here, we combined a loss of function approach with stable isotope labeling with amino acids in cell culture (SILAC)-based mass spectrometry (MS) to investigate the role of the mitogen-activated protein kinase kinase 5 (MKK5) in T. brucei. The silencing of MKK5 significantly decreased the proliferation of procyclic forms of T. brucei. To shed light on the molecular alterations associated with this phenotype, we measured the total proteome and phosphoproteome of cells silenced for MKK5. In the total proteome, we observed a general decrease in proteins related to ribosome and translation as well as down-regulation of several components of the fatty acids biosynthesis pathway. In addition, we observed alterations in the protein levels and phosphorylation of key metabolic enzymes, which point toward a suppression of the oxidative metabolism. Taken together, our findings show that the silencing of MKK5 alters cell growth, energy metabolism, protein and fatty acids biosynthesis in procyclic T. brucei.


Asunto(s)
MAP Quinasa Quinasa 5/fisiología , Trypanosoma brucei brucei/crecimiento & desarrollo , Proliferación Celular , Metabolismo Energético , Ácidos Grasos/biosíntesis , Silenciador del Gen , MAP Quinasa Quinasa 5/genética , Espectrometría de Masas , Biosíntesis de Proteínas , Trypanosoma brucei brucei/enzimología
2.
Biochim Biophys Acta ; 1813(10): 1854-62, 2011 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-21767578

RESUMEN

Hepatitis C virus (HCV) is an RNA positive strand virus, member of the Flaviviridae family. The viral particle is composed of a capsid containing the genome, surrounded by E1 and E2 proteins, however different forms of viral particles have been observed including non-enveloped particles. Previous reports have proposed that hepatitis C non-enveloped capsid-like particles (HCVne) enter cells of hepatic origin via clathrin-mediated endocytosis, during which different signaling events occur. In this report we show that HCVne particles are capable of inducing the recently discovered ERK5 pathway, in a dose dependent way. The ERK5 pathway can be activated by growth factors and other extracellular signals. This specific activation occurs through a well characterized upstream kinase, MEK5, and is capable of inducing gene regulation of mef2. In contrast, when HCV core structural and NS5A non-structural proteins were expressed endogenously no activation of this pathway was detected. These cell signaling events could be of critical importance and might give clues for the elucidation of cellular manifestations associated with HCV infection.


Asunto(s)
Proteínas de la Cápside/farmacología , Hepacivirus , Proteínas de Dominio MADS/metabolismo , MAP Quinasa Quinasa 5/metabolismo , Proteína Quinasa 7 Activada por Mitógenos/metabolismo , Factores Reguladores Miogénicos/metabolismo , Virión/fisiología , Animales , Células Cultivadas , Relación Dosis-Respuesta a Droga , Células Hep G2 , Hepacivirus/fisiología , Humanos , Proteínas de Dominio MADS/fisiología , MAP Quinasa Quinasa 5/fisiología , Factores de Transcripción MEF2 , Proteína Quinasa 7 Activada por Mitógenos/fisiología , Modelos Biológicos , Factores Reguladores Miogénicos/fisiología , Transducción de Señal/efectos de los fármacos , Spodoptera , Proteínas del Núcleo Viral/farmacología , Proteínas del Envoltorio Viral/farmacología , Proteínas no Estructurales Virales/farmacología
3.
Br J Cancer ; 104(4): 664-72, 2011 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-21266977

RESUMEN

BACKGROUND: Aberrant mitogen/extracellular signal-regulated kinase 5 (MEK5)-extracellular signal-regulated protein kinase 5 (ERK5)-mediated signalling has been implicated in a number of tumour types including prostate cancer (PCa). The molecular basis of ERK5-driven carcinogenesis and its clinical relevance remain to be fully characterised. METHODS: Modulation of ERK5 expression or function in human PCa PC3 and PC3-ERK5 (stably transfected with ERK5) cells was performed using siRNA-mediated knockdown or the MEK inhibitor PD18435 respectively. In vitro significance of ERK5 signalling was assessed by assays for proliferation, motility, invasion and invadopodia. Expression of matrix metalloproteinases/tissue inhibitors of metalloproteases was determined by Q-RT-PCR. Extracellular signal-regulated protein kinase 5 expression in primary and metastatic PCa was examined using immunohistochemistry. RESULTS: Reduction of ERK5 expression or signalling significantly inhibited the motility and invasive capability of PC3 cells. Extracellular signal-regulated protein kinase 5-mediated signalling significantly promoted formation of in vivo metastasis in an orthotopic PCa model (P<0.05). Invadopodia formation was also enhanced by forced ERK5 expression in PC3 cells. Furthermore, in metastatic PCa, nuclear ERK5 immunoreactivity was significantly upregulated when compared with benign prostatic hyperplasia and primary PCa (P=0.013 and P<0.0001, respectively). CONCLUSION: Our in vitro, in vivo and clinical data support an important role for the MEK5-ERK5 signalling pathway in invasive PCa, which represents a potential target for therapy in primary and metastatic PCa.


Asunto(s)
Proteína Quinasa 7 Activada por Mitógenos/fisiología , Hiperplasia Prostática/patología , Neoplasias de la Próstata/patología , Animales , Benzamidas/farmacología , Movimiento Celular/efectos de los fármacos , Movimiento Celular/genética , Proliferación Celular/efectos de los fármacos , Células Cultivadas , Evaluación Preclínica de Medicamentos , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Regulación Neoplásica de la Expresión Génica/genética , Humanos , MAP Quinasa Quinasa 5/genética , MAP Quinasa Quinasa 5/metabolismo , MAP Quinasa Quinasa 5/fisiología , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Sistema de Señalización de MAP Quinasas/genética , Sistema de Señalización de MAP Quinasas/fisiología , Masculino , Ratones , Ratones Desnudos , Proteína Quinasa 7 Activada por Mitógenos/genética , Proteína Quinasa 7 Activada por Mitógenos/metabolismo , Invasividad Neoplásica , Fenotipo , Hiperplasia Prostática/genética , Hiperplasia Prostática/metabolismo , Neoplasias de la Próstata/genética , Neoplasias de la Próstata/metabolismo , Inhibidores de Proteínas Quinasas/farmacología , ARN Interferente Pequeño/farmacología , Transfección , Trasplante Heterólogo
4.
Cardiovasc Res ; 85(3): 514-9, 2010 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-19815564

RESUMEN

AIMS: Resveratrol activates Sirtuin 1 (SIRT1), a nicotinamide adenine dinucleotide-dependent deacetylase which modulates metabolic homeostasis and improves several pathophysiological features present in diseases of ageing. In particular, it has been shown that SIRT1 activation improves endothelial dysfunction and suppresses vascular inflammation, two central pathophysiological processes involved in the initiation and progression of cardiovascular disease. The downstream targets of SIRT1 activation in this context, however, remain poorly defined. Therefore, in this study, we aimed to characterize mechanistically how SIRT1 activation regulates the endothelial vasoprotective phenotype. METHODS AND RESULTS: We demonstrate that SIRT1 activation by resveratrol increases the expression of the transcription factor Krüppel-like factor 2 (KLF2) in human vascular endothelial cells, resulting in the orchestrated regulation of transcriptional programs critical for conferring an endothelial vasoprotective phenotype. Moreover, we show that KLF2 upregulation by resveratrol occurs via a mitogen-activated protein kinase 5/myocyte enhancing factor 2-dependent signalling pathway. CONCLUSION: Collectively, these observations provide a new mechanistic framework to understand the vascular protective effects mediated by SIRT1 activators and define KLF2 as a critical mediator of these effects.


Asunto(s)
Células Endoteliales/efectos de los fármacos , Factores de Transcripción de Tipo Kruppel/genética , Sirtuina 1/fisiología , Estilbenos/farmacología , Adenilato Quinasa/fisiología , Células Cultivadas , Regulación de la Expresión Génica/efectos de los fármacos , Humanos , Proteínas de Dominio MADS/fisiología , MAP Quinasa Quinasa 5/fisiología , Factores de Transcripción MEF2 , Proteína Quinasa 7 Activada por Mitógenos/fisiología , Factores Reguladores Miogénicos/fisiología , Óxido Nítrico Sintasa de Tipo III/genética , Fenotipo , Resveratrol
5.
Hypertens Res ; 30(11): 1107-17, 2007 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-18250560

RESUMEN

Big mitogen-activated protein kinase 1 (BMK1), also known as extracellular signal-regulated kinase 5 (ERK5), is a newly identified member of the mitogen-activated protein (MAP) kinase family. Recently, several studies have suggested that BMK1 plays an important role in the pathogenesis of cardiovascular disease. To clarify the pathophysiological significance of BMK1 in the process of vascular remodeling, we explored the molecular mechanisms of BMK1 activation in vascular smooth muscle cells (VSMCs). From the results of co-immunoprecipitation and immunoblotting analyses, it was found that platelet-derived growth factor (PDGF), a known potent mitogen, activated BMK1 and triggered the Gab1-SHP-2 interaction in rat aortic smooth muscle cells (RASMCs). The abrogation of SHP-2 phosphatase activity by transfection of the SHP-2-C/S mutant suppressed PDGF-stimulated BMK1 activation. Infection with an adenoviral vector expressing dominant-negative MEK5alpha, which can suppress PDGF-stimulated BMK1 activation to the control level, inhibited PDGF-induced RASMC migration. Moreover, we observed an increase of BMK1 activation in injured mouse femoral arteries. From these findings, it is suggested that BMK1 activation leads to VSMC migration induced by PDGF via Gab1-SHP-2 interaction, and that BMK1-mediated VSMC migration may play a role in the pathogenesis of vascular remodeling.


Asunto(s)
Proteína Quinasa 7 Activada por Mitógenos/fisiología , Músculo Liso Vascular/citología , Miocitos del Músculo Liso/fisiología , Factor de Crecimiento Derivado de Plaquetas/farmacología , Animales , Movimiento Celular/efectos de los fármacos , Humanos , MAP Quinasa Quinasa 5/fisiología , Masculino , Ratones , Ratones Endogámicos C57BL , Proteína Quinasa 1 Activada por Mitógenos/fisiología , Proteína Quinasa 3 Activada por Mitógenos/fisiología , Fosfoproteínas/metabolismo , Fosforilación , Proteína Tirosina Fosfatasa no Receptora Tipo 11/metabolismo , Ratas
6.
Mol Cell Biol ; 25(1): 336-45, 2005 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-15601854

RESUMEN

To elucidate the physiological significance of MEK5 in vivo, we have examined the effect of mek5 gene elimination in mice. Heterozygous mice appear to be healthy and were fertile. However, mek5(-/-) embryos die at approximately embryonic day 10.5 (E10.5). The phenotype of the mek5(-/-) embryos includes abnormal cardiac development as well as a marked decrease in proliferation and an increase in apoptosis in the heart, head, and dorsal regions of the mutant embryos. The absence of MEK5 does not affect cell cycle progression but sensitizes mouse embryonic fibroblasts (MEFs) to the ability of sorbitol to enhance caspase 3 activity. Further studies with mek5(-/-) MEFs indicate that MEK5 is required for mediating extracellular signal-regulated kinase 5 (ERK5) activation and for the regulation of the transcriptional activity of myocyte enhancer factor 2. Overall, this is the first study to rigorously establish the role of MEK5 in vivo as an activator of ERK5 and as an essential regulator of cell survival that is required for normal embryonic development.


Asunto(s)
Proteínas de Unión al ADN/genética , MAP Quinasa Quinasa 5/genética , MAP Quinasa Quinasa 5/fisiología , Proteína Quinasa 7 Activada por Mitógenos/genética , Factores de Transcripción/genética , Animales , Apoptosis , Southern Blotting , Caspasa 3 , Caspasas/metabolismo , Muerte Celular , Proliferación Celular , Supervivencia Celular , Células Cultivadas , Activación Enzimática , Fibroblastos/metabolismo , Citometría de Flujo , Eliminación de Gen , Genes Reporteros , Vectores Genéticos , Genotipo , Heterocigoto , Immunoblotting , Inmunohistoquímica , Etiquetado Corte-Fin in Situ , Luciferasas/metabolismo , Factores de Transcripción MEF2 , Ratones , Ratones Noqueados , Modelos Genéticos , Mutación , Miocardio/metabolismo , Factores Reguladores Miogénicos , Fenotipo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Transducción de Señal , Factores de Tiempo , Distribución Tisular , Transcripción Genética , Activación Transcripcional , Transgenes
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...